ABI Expands Biomarker Collaboration with Stanford, U of Miami to Include TaqMan Array

NEW YORK, Jan. 10 (GenomeWeb News) - Applied Biosystems has expanded an ongoing collaboration with researchers at Stanford University and the University of Miami to further study lymphoma biomarkers, the company said today.

In the new studies, the scientists will use ABI's TaqMan Low Density Array, a microfluidic card for real-time PCR, to validate the predictive value of six gene-expression based markers associated with treatment response and survival in diffuse large B cell lymphoma, the most common form of non-Hodgkin's lymphoma.

The initial study was published last April in an article in the New England Journal of Medicine entitled "Prediction of survival in diffuse large B-cell lymphoma based on the expression of six genes." For this study, the researchers used a combination of microarrays, bioinformatics, real-time PCR, and TaqMan gene expression assays, ABI said.